Companies › OriCell Therapeutics
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OriCAR-017 GPRC5D-directed chimeric antigen receptor (CAR) modified T cells | GPRC5D | Phase 1 | Relapsed and/or Refractory Multiple Myeloma; Neoplasms, Plasma Cell | Nov 2026 |
| Ori-C101 GPC3-directed CAR-T cell therapy | GPRC3 | Phase 1 | Hepatocellular Carcinoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06182696 | OriCAR-017 | Phase 1 | Relapsed and/or Refractory Multiple Myeloma | Oncology | Nov 2026 |
| NCT06271252 | OriCAR-017 | Phase 1 | Neoplasms, Plasma Cell | Oncology | Dec 2026 |
| NCT05652920 | Ori-C101 | Phase 1 | Hepatocellular Carcinoma | Oncology | Dec 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.